Published in J Neurochem on June 01, 2004
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
The shock of aging: molecular chaperones and the heat shock response in longevity and aging--a mini-review. Gerontology (2009) 1.69
What Are the bona fide GSK3 Substrates? Int J Alzheimers Dis (2011) 1.65
Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J Cell Biol (2005) 1.59
Synapses and Alzheimer's disease. Cold Spring Harb Perspect Biol (2012) 1.57
New directions for frontotemporal dementia drug discovery. Alzheimers Dement (2007) 1.53
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52
Single-gene disorders: what role could moonlighting enzymes play? Am J Hum Genet (2005) 1.52
The role of GSK-3 in synaptic plasticity. Br J Pharmacol (2008) 1.52
Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res (2012) 1.48
Targets and consequences of protein SUMOylation in neurons. Brain Res Rev (2010) 1.44
Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta. J Neurosci (2011) 1.44
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39
Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry (2009) 1.28
GSK3beta is a negative regulator of platelet function and thrombosis. Blood (2008) 1.27
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol (2011) 1.22
GSK-3β: A Bifunctional Role in Cell Death Pathways. Int J Cell Biol (2012) 1.21
The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease. Mol Neurodegener (2008) 1.20
Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-β precursor protein. Mol Cell Biol (2012) 1.18
Inhibition of glycogen synthase kinase 3beta (GSK3beta) decreases inflammatory responses in brain endothelial cells. Am J Pathol (2010) 1.17
Glycogen synthase kinase-3α limits ischemic injury, cardiac rupture, post-myocardial infarction remodeling and death. Circulation (2011) 1.09
Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death. J Biol Chem (2012) 1.07
Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. Eur Arch Psychiatry Clin Neurosci (2008) 1.03
Pharmacology of signaling induced by dopamine D(1)-like receptor activation. Pharmacol Ther (2010) 1.02
Glycogen synthase kinase 3 alpha and 3 beta have distinct functions during cardiogenesis of zebrafish embryo. BMC Dev Biol (2007) 1.02
Lithium enhances remyelination of peripheral nerves. Proc Natl Acad Sci U S A (2012) 1.01
Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models. Int J Alzheimers Dis (2012) 0.99
N-acetylcholinesterase-induced apoptosis in Alzheimer's disease. PLoS One (2008) 0.98
Functional MRI of delayed chronic lithium treatment in rat focal cerebral ischemia. Stroke (2008) 0.96
Glycogen synthase kinase 3beta inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neurons. Neuro Oncol (2011) 0.95
Neuroprotective actions of selective estrogen receptor modulators. Psychoneuroendocrinology (2009) 0.95
Cell signaling pathways in the mechanisms of neuroprotection afforded by bergamot essential oil against NMDA-induced cell death in vitro. Br J Pharmacol (2007) 0.95
PP2A and GSK-3beta act antagonistically to regulate active zone development. J Neurosci (2009) 0.94
Effects of the A(-115)G variant on CREB1 promoter activity in two brain cell lines: Interactions with gonadal steroids. Am J Med Genet B Neuropsychiatr Genet (2010) 0.93
Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp Mol Med (2015) 0.93
A chemical compound commonly used to inhibit PKR, {8-(imidazol-4-ylmethylene)-6H-azolidino[5,4-g] benzothiazol-7-one}, protects neurons by inhibiting cyclin-dependent kinase. Eur J Neurosci (2008) 0.93
The Wnt-dependent signaling pathways as target in oncology drug discovery. Invest New Drugs (2006) 0.93
Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci (Elite Ed) (2012) 0.92
A GSK-3β inhibitor protects against radiation necrosis in mouse brain. Int J Radiat Oncol Biol Phys (2014) 0.92
Lithium regulates keratinocyte proliferation via glycogen synthase kinase 3 and NFAT2 (nuclear factor of activated T cells 2). J Cell Physiol (2012) 0.92
Pharmacotherapeutic targets in Alzheimer's disease. J Cell Mol Med (2008) 0.91
Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3. Mol Biochem Parasitol (2010) 0.90
Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease. Alzheimers Dement (2013) 0.89
Natural antisense transcripts are co-expressed with sense mRNAs in synaptoneurosomes of adult mouse forebrain. Neurosci Res (2008) 0.89
Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim Biophys Acta (2014) 0.88
The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain. J Pharm Pharmacol (Los Angel) (2013) 0.88
Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease. Neuropsychopharmacology (2013) 0.88
Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system. Pharmacol Rev (2014) 0.87
Activity-dependent regulation of dendritic growth and maintenance by glycogen synthase kinase 3β. Nat Commun (2013) 0.86
Tau acts as a mediator for Alzheimer's disease-related synaptic deficits. Eur J Neurosci (2014) 0.85
Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx (2005) 0.85
Dependence of NMDA/GSK-3β mediated metaplasticity on TRPM2 channels at hippocampal CA3-CA1 synapses. Mol Brain (2011) 0.84
Effects of the G(-656)A variant on CREB1 promoter activity in a neuronal cell line: interactions with gonadal steroids and stress. Mol Psychiatry (2008) 0.84
Melatonin Potentiates the Neuroprotective Properties of Resveratrol Against Beta-Amyloid-Induced Neurodegeneration by Modulating AMP-Activated Protein Kinase Pathways. J Clin Neurol (2010) 0.84
Age-related neuroinflammation and changes in AKT-GSK-3β and WNT/ β-CATENIN signaling in rat hippocampus. Aging (Albany NY) (2015) 0.83
Serotonin transporter and saitohin genes in risk of Alzheimer's disease and frontotemporal lobar dementia: preliminary findings. Neurol Sci (2010) 0.83
TNF-induced activation of pulmonary microvessel endothelial cells: a role for GSK3beta. Am J Physiol Lung Cell Mol Physiol (2009) 0.82
Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors. J Mol Model (2009) 0.82
Hypothermia-induced hyperphosphorylation: a new model to study tau kinase inhibitors. Sci Rep (2012) 0.82
Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. Curr Neuropharmacol (2007) 0.82
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. Biomed Res Int (2016) 0.81
Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update. ScientificWorldJournal (2012) 0.81
Potential application of lithium in Parkinson's and other neurodegenerative diseases. Front Neurosci (2015) 0.81
Pro-apoptotic protein-protein interactions of the extended N-AChE terminus. J Neural Transm (Vienna) (2009) 0.80
Low dose Hsp90 inhibitor 17AAG protects neural progenitor cells from ischemia induced death. J Cell Commun Signal (2014) 0.80
Formation of the blood-brain barrier: Wnt signaling seals the deal. J Cell Biol (2008) 0.80
Activation of glycogen synthase kinase 3β ameliorates diabetes-induced kidney injury. J Biol Chem (2014) 0.80
Valproate Inhibits Methamphetamine Induced Hyperactivity via Glycogen Synthase Kinase 3β Signaling in the Nucleus Accumbens Core. PLoS One (2015) 0.80
Evaluation of acute antiapoptotic effects of Li+ in neuronal cell cultures. J Neural Transm (Vienna) (2006) 0.80
Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases. Neurobiol Dis (2009) 0.80
Regulation of mineral metabolism by lithium. Pflugers Arch (2013) 0.79
Parallels between major depressive disorder and Alzheimer's disease: role of oxidative stress and genetic vulnerability. Cell Mol Neurobiol (2014) 0.79
Present and prospective clinical therapeutic regimens for Alzheimer's disease. Neuropsychiatr Dis Treat (2008) 0.79
The mitochondria-targeted antioxidants and remote kidney preconditioning ameliorate brain damage through kidney-to-brain cross-talk. PLoS One (2012) 0.79
The Role of α-Synuclein and LRRK2 in Tau Phosphorylation. Parkinsons Dis (2015) 0.78
Tumor necrosis factor-α induces increased lung vascular permeability: a role for GSK3α/β. Eur J Pharmacol (2011) 0.78
Azaphilones inhibit tau aggregation and dissolve tau aggregates in vitro. ACS Chem Neurosci (2015) 0.78
Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking. J Comput Aided Mol Des (2008) 0.77
Synergistic effects of GSK-3β and HDAC inhibitors in intracerebroventricular streptozotocin-induced cognitive deficits in rats. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.77
4-Aminoethylamino-emodin--a novel potent inhibitor of GSK-3beta--acts as an insulin-sensitizer avoiding downstream effects of activated beta-catenin. J Cell Mol Med (2009) 0.77
BBB-Permeable, Neuroprotective, and Neurotrophic Polysaccharide, Midi-GAGR. PLoS One (2016) 0.77
In vivo modification of Abeta plaque toxicity as a novel neuroprotective lithium-mediated therapy for Alzheimer's disease pathology. Acta Neuropathol Commun (2013) 0.76
Role of Glycogen Synthase Kinase-3β in APP Hyperphosphorylation Induced by NMDA Stimulation in Cortical Neurons. Pharmaceuticals (Basel) (2010) 0.75
GSK3β inhibition accelerates axon debris clearance and new axon remyelination. Am J Transl Res (2016) 0.75
Modulation of glycogen synthase kinase-3β following TRAIL combinatorial treatment in cancer cells. Oncotarget (2016) 0.75
Biscogniauxone, a New Isopyrrolonaphthoquinone Compound from the Fungus Biscogniauxia mediterranea Isolated from Deep-Sea Sediments. Mar Drugs (2016) 0.75
Roles of GSK3β in odor habituation and spontaneous neural activity of the mouse olfactory bulb. PLoS One (2013) 0.75
A transitory activation of protein kinase-A induces a sustained tau hyperphosphorylation at multiple sites in N2a cells-imply a new mechanism in Alzheimer pathology. J Neural Transm (Vienna) (2006) 0.75
In vivo regulation of glycogen synthase kinase 3β activity in neurons and brains. Sci Rep (2017) 0.75
Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. PLoS One (2017) 0.75
Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem (2003) 2.65
Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ Res (2007) 2.22
Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci (2003) 1.83
Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 1.50
Extracellular tau is toxic to neuronal cells. FEBS Lett (2006) 1.47
Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci (2006) 1.44
Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem (2002) 1.42
Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med (2002) 1.34
Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem (2006) 1.34
GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol (2009) 1.32
Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis (2003) 1.29
Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J Alzheimers Dis (2009) 1.29
Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell (2006) 1.29
Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J Biol Chem (2003) 1.19
Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett (2011) 1.17
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis (2005) 1.16
N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem (2007) 1.15
Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem (2010) 1.15
A role of MAP1B in Reelin-dependent neuronal migration. Cereb Cortex (2004) 1.13
Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis (2005) 1.11
Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem J (2003) 1.11
Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Mol Cell Biochem (2010) 1.08
Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis (2009) 1.06
Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging (2005) 1.05
Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int J Exp Pathol (2008) 1.04
Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J Neurosci (2004) 1.04
Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J (2007) 1.04
Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des (2010) 1.04
A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy. Arch Neurol (2005) 1.04
MAP1B is required for Netrin 1 signaling in neuronal migration and axonal guidance. Curr Biol (2004) 1.04
Glycogen synthase kinase-3 is activated in neuronal cells by Galpha12 and Galpha13 by Rho-independent and Rho-dependent mechanisms. J Neurosci (2002) 1.03
Chronological primacy of oxidative stress in Alzheimer disease. Neurobiol Aging (2005) 1.02
Creating a transatlantic research enterprise for preventing Alzheimer's disease. Alzheimers Dement (2009) 1.02
The role of GSK3 in Alzheimer disease. Brain Res Bull (2009) 1.00
MAP1B regulates microtubule dynamics by sequestering EB1/3 in the cytosol of developing neuronal cells. EMBO J (2013) 1.00
Deconstructing mitochondrial dysfunction in Alzheimer disease. Oxid Med Cell Longev (2013) 0.99
GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus (2010) 0.99
The influence of phospho-τ on dendritic spines of cortical pyramidal neurons in patients with Alzheimer's disease. Brain (2013) 0.99
Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease. Ann N Y Acad Sci (2005) 0.99
GSK3 inhibitors and disease. Mini Rev Med Chem (2009) 0.98
The role of glycogen synthase kinase 3 in the early stages of Alzheimers' disease. FEBS Lett (2008) 0.98
Alpha-helix structure in Alzheimer's disease aggregates of tau-protein. Biochemistry (2002) 0.98
Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord (2002) 0.98
Role of MAP1B in axonal retrograde transport of mitochondria. Biochem J (2006) 0.97
Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease: Cross-Talk with P-tau and β-Amyloid. Front Mol Neurosci (2011) 0.97
Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur J Biochem (2002) 0.96
Microtubule-associated protein 1B (MAP1B) is required for dendritic spine development and synaptic maturation. J Biol Chem (2011) 0.95
Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res (2003) 0.95
Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by α7 and β2* nicotinic stimulation. Toxicol Sci (2011) 0.94
Tau overexpression results in its secretion via membrane vesicles. Neurodegener Dis (2012) 0.94
Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides (2002) 0.94
Glycogen Synthase Kinase-3 Modulates Neurite Outgrowth in Cultured Neurons: Possible Implications for Neurite Pathology in Alzheimer's Disease. J Alzheimers Dis (1999) 0.92
Three-dimensional structure of human tubulin chaperone cofactor A. J Mol Biol (2002) 0.92
GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. Neurobiol Aging (2003) 0.91
Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease. Biochim Biophys Acta (2004) 0.91
Characteristics of the binding of thioflavin S to tau paired helical filaments. J Alzheimers Dis (2006) 0.90
Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. Mediators Inflamm (2013) 0.90
Microtubule-associated protein 1B interaction with tubulin tyrosine ligase contributes to the control of microtubule tyrosination. Dev Neurosci (2008) 0.89
Expression of the ghrelin and neurotensin systems is altered in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis (2010) 0.89
Binding of microtubule-associated protein 1B to LIS1 affects the interaction between dynein and LIS1. Biochem J (2005) 0.89
Alzheimer disease: caspases first. Nat Rev Neurol (2010) 0.89
GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration. Front Mol Neurosci (2011) 0.88
Tangling with hypothermia. Nat Med (2004) 0.88
Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin. Neurotox Res (2004) 0.88
Tau aggregates and tau pathology. J Alzheimers Dis (2008) 0.88
End binding protein-1 (EB1) complements microtubule-associated protein-1B during axonogenesis. J Neurosci Res (2005) 0.87
Neuronal microtubule-associated protein 2D is a dual a-kinase anchoring protein expressed in rat ovarian granulosa cells. J Biol Chem (2004) 0.87
Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. J Alzheimers Dis (2009) 0.87
M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway. Neurobiol Dis (2004) 0.87
Tau regulates the localization and function of End-binding proteins 1 and 3 in developing neuronal cells. J Neurochem (2015) 0.86
The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol Dis (2005) 0.86
Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol Neurodegener (2007) 0.86
Further understanding of tau phosphorylation: implications for therapy. Expert Rev Neurother (2015) 0.86
Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation. Neurosci Lett (2007) 0.86
Nuclear localization of N-terminal mutant huntingtin is cell cycle dependent. Eur J Neurosci (2002) 0.86
Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers. Neurosci Lett (2004) 0.85
Tau deficiency leads to the upregulation of BAF-57, a protein involved in neuron-specific gene repression. FEBS Lett (2010) 0.85
P24, a glycogen synthase kinase 3 (GSK 3) inhibitor. Biochim Biophys Acta (2002) 0.85
Function of tau protein in adult newborn neurons. FEBS Lett (2009) 0.85
The involvement of cholinergic neurons in the spreading of tau pathology. Front Neurol (2013) 0.84
Expression of Somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis (2010) 0.84
Dual effects of increased glycogen synthase kinase-3β activity on adult neurogenesis. Hum Mol Genet (2012) 0.84
Quinones facilitate the self-assembly of the phosphorylated tubulin binding region of tau into fibrillar polymers. Biochemistry (2004) 0.84
Tau isoform with three microtubule binding domains is a marker of new axons generated from the subgranular zone in the hippocampal dentate gyrus: implications for Alzheimer's disease. J Alzheimers Dis (2012) 0.83
Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation. J Alzheimers Dis (2002) 0.83
Tau protein and adult hippocampal neurogenesis. Front Neurosci (2012) 0.83
Tau regulates the subcellular localization of calmodulin. Biochem Biophys Res Commun (2011) 0.82
Heme catabolism and heme oxygenase in neurodegenerative disease. Antioxid Redox Signal (2004) 0.82
Memantine inhibits calpain-mediated truncation of GSK-3 induced by NMDA: implications in Alzheimer's disease. J Alzheimers Dis (2009) 0.82
Altered Ca2+ dependence of synaptosomal plasma membrane Ca2+-ATPase in human brain affected by Alzheimer's disease. FASEB J (2009) 0.82
Patient-derived olfactory mucosa cells but not lung or skin fibroblasts mediate axonal regeneration of retinal ganglion neurons. Neurosci Lett (2011) 0.81
Calpain-mediated truncation of GSK-3 in post-mortem brain samples. J Neurosci Res (2009) 0.81
Altered expression of brain acetylcholinesterase in FTDP-17 human tau transgenic mice. Neurobiol Aging (2011) 0.81
MDMA impairs mitochondrial neuronal trafficking in a Tau- and Mitofusin2/Drp1-dependent manner. Arch Toxicol (2014) 0.81
Alterations in the nuclear architecture produced by the overexpression of tau protein in neuroblastoma cells. J Alzheimers Dis (2013) 0.81
Expression of an altered form of tau in Sf9 insect cells results in the assembly of polymers resembling Alzheimer's paired helical filaments. Brain Res (2004) 0.81
Selenomethionine incorporation into amyloid sequences regulates fibrillogenesis and toxicity. PLoS One (2011) 0.81
Acetylcholine receptors and tau phosphorylation. Curr Mol Med (2006) 0.81
Olfactory Ensheathing Glia: Drivers of Axonal Regeneration in the Central Nervous System? J Biomed Biotechnol (2002) 0.80
Characterization by atomic force microscopy and cryoelectron microscopy of tau polymers assembled in Alzheimer's disease. J Alzheimers Dis (2001) 0.80